Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases Please visit their website for more information.
*Proprietary Buy Sell Volume Indicator
| Revenue: $3M |
| Revenue Growth (YOY): 58.86% |
| Profit (% of Rev): 100.00% |
| Income (% of Rev): -259.59% |
| Income Growth (YOY): -21.31% |
| Operating Income: $-9M |
| Operating Cash Flow: $-8M |
| Operating Cash Flow Growth (YoY): -3.49% |
| Annual Dividend Yield: 0.00% |
| Total Assets: $45M |
| Total Liabilities: $19M |
| Cash & Equivalent: $32M |
| Total Debt: $10M |
| Debt/Equity: 0.37 |
| Quick Ratio: 2.22 |
| Current Ratio: 2.22 |
| Price/Book: 1.53 |
| Price/Earnings: -1.12 |
| EBITDA: $-9M |
| EPS: -0.17 |
Our proprietary analysis employs a weighted average approach integrating both functional and technical parameters, tailored to the sector, industry, and microeconomic factors. This methodology assigns dynamic weights to the parameters, with a focus on recent trends, ensuring a nuanced evaluation for informed investment decisions. Considering all the above parameters, in addition to some of the derived parameters of the stock in conjunction with its sector and macroeconomic conditions, our proprietary Weighted Average AI model gives a rank of Buy.
TheoryofStocks is not registered as an investment advisor with any regulatory authority. The information provided on this Website is for educational purposes only and should not be construed as financial or investment advice. By continuing to use this site, you are agreeing to the Terms of Use and Privacy Policy. Please read our Disclaimer.
Contact @ support@theoryofstocks.com
© 2024 Stock Articles. All rights reserved.